We have acknowledged with great attention the recent article of Leclerc et al. 1 reporting a synergistic cytotoxicity of methotrexate (MTX) and histone deacetylase inhibitors (HDACis) combination treatment in childhood acute lymphoblastic leukemia (ALL) cell lines. Both the group of Leclerc 1 and ours 2 have suggested that the introduction of HDACis into current ALL therapy regimes may provide a promising alternative. Leclerc et al. 1 have observed synergism after sequential treatment with MTX followed by the HDACi suberoylanilide hydroxamic acid (SAHA). However, when we changed the sequence of application by treating cells primarily with different HDACis, such as SAHA and valproic acid (VPA), and afterwards with MTX or combined MTX and HDACi concomitantly, a strong antagonistic effect was observed.
We used experimental settings similar to those presented by Leclerc et al. 1 Briefly, cells of the B-cell precursor (BCP) ALL cell line Nalm6 were exposed to MTX (300 nM) or SAHA (1 mM) alone, or a sequence of SAHA followed by MTX. As shown in Figure 1a , treatment with SAHA followed by MTX significantly decreased the proportion of apoptotic Nalm6 cells compared with MTX alone (Po0.001), showing that the sequence of application has a significant effect on drug responsiveness. To test our observation in different conditions, we treated cells of the BCP-ALL cell line Reh with MTX (60 nM) or VPA (1.65 mM) as another HDACi, again alone or by applying both drugs sequentially. Incubation time with each compound was extended to 48 h and the absolute count of vital cells was assessed by flow cytometry. As shown in Figure 1b , sequential treatment with MTX followed by VPA decreased the amount of vital Reh cells significantly compared with administration of single drugs MTX and VPA (Po0.001), confirming the results reported by Leclerc et al. 1 The sequential combination of both drugs in reversed order (VPA followed by MTX) was significantly less effective in reducing vital cell counts compared with administration of each drug alone (Po0.01). Taken together, altering the application schedule reversed the described synergistic effect 1 and actually had a potent antagonistic effect on treatment responsiveness of BCP-ALL cells.
A synergistic interaction turning into antagonism upon changing of treatment sequence raises the question as to what kind of interaction might occur after simultaneous application of both drugs. Consequently, we tested the effect of concomitant treatment with MTX at two dose levels and two different HDACis, SAHA and VPA, in BCP-and T-ALL cell lines. Figure 2a shows the results of concomitant treatment in BCP-ALL cell line Nalm6. Apoptosis induced by 80 nM MTX was reduced significantly when combined with VPA (Po0.001) or SAHA (Po0.001). Combinations of 20 nM MTX with each HDACi produced no significant difference compared with VPA (P ¼ 0.155) or SAHA (P ¼ 0.190) alone. In order to evaluate combination effects, we used the fractional product method of Webb.
3 Antagonism for each of these concomitant combinations was confirmed by fractional product calculations as summarized in Table 1 . Applying this treatment scheme to T-ALL cell lines Molt-4 and Jurkat provided comparable results. The majority of combinations tested were clearly antagonistic. Synergism was observed in none of the concomitant combinations tested. Consistently with our observations, concomitant combinations of MTX with different HDACis have been published to result in antagonistic effects in a variety of tumor entities in vitro.
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Furthermore, we analyzed the effect of concomitant treatment with MTX and/or VPA on Nalm6 cell cycle distributions during a 72-h time course (Figure 2b ). Treatment with MTX alone resulted in an accumulation of cells in G0/1 and S phase at 24 h, followed by a potent shift towards the sub-G1 peak, indicating DNA fragmentation and apoptosis at subsequent time points. VPA induced an accumulation of cells mainly in G0/1 phase and a nearly complete loss of S phase after 24 h of treatment. After 48 h VPA-treated cells entered again into S phase, indicating a resumption of proliferative activity, which resulted in a cell cycle distribution comparable to that of the untreated control at 72 h. The apoptotic sub-G1 peak in VPA-exposed cells was moderately increased compared with untreated controls. Concomitant treatment with MTX and VPA produced cell cycle distributions largely resembling those of VPA alone, confirming again an antagonistic interaction. MTX as an S-phase selective agent might be especially prone to treatment sequence-specific drug interactions. For example, exposure of L5178Y murine leukemia cells to MTX followed by asparaginase produces synergistic effects, whereas reversal of the treatment sequence results in antagonism. 6 It was shown that asparaginase pre-treatment inhibited intracellular accumulation of MTX polyglutamates, which have a central role in mediating MTX cytotoxicity. Furthermore, it has been observed that asparaginase induced a temporary inhibition of leukemia cell proliferation, as shown by a reversible loss of S-phase cells in cell cycle distributions. Interestingly, the extent of inhibition and recovery of MTX polyglutamate accumulation in the asparaginase pre-treated cells largely paralleled the inhibition and recovery of DNA synthesis. 6 Further studies supported the assumption that cellular accumulation of MTX polyglutamates, and thereby MTX cytotoxicity, is directly related to the proliferation rate of tumor cells. 7 With regard to our experiments, it seems possible that the temporary loss of S-phase cells in cultures treated with VPA or the combination of VPA and MTX might contribute to the sequencespecific antagonism of MTX and HDACi in a similar way as was shown for MTX and asparaginase.
Exposure of leukemia cells to HDACis seems to cause opposing effects. HDACi treatment induces gene expression changes that favor MTX polyglutamylation and cytotoxicity 1 but at the same time cause a temporary cell cycle arrest, which possibly counteracts MTX's polyglutamate accumulation and reduces its cytotoxic efficacy. The sequence of drug application seems to determine which of these two effects overrules the other, resulting in either synergistic or antagonistic interaction.
Leclerc et al.
1 suggest that the synergism observed for the combination of MTX followed by HDACis warrants further testing in clinical studies. In the in vitro setting, elimination of a drug was achieved by replacement of culture medium, which allows a clearly defined sequence of exposure to each compound without overlap. MTX serum levels in patients treated according to established ALL therapy regimens reach a steady state during the infusion period, followed by a continuous decrease over two to three days. 8 Owing to this slow elimination of MTX and perceiving that concomitant treatment with MTX and HDACis or reversal of treatment sequence results in potent antagonism in vitro, careful determination of the time point for HDACi application after MTX treatment has to be considered in the clinical setting. Additionally, it seems desirable to investigate whether HDACis could also enhance the anti-leukemic efficacy of other ALL therapy elements that might be less susceptible to HDACi-related cell cycle effects than MTX. 
